Clinical trials: Asthma, completed
Asthma
Evaluation of Safety and Tolerability of BI 894416 in Patients With Mild Asthma
In both parts, the primary comparisons of interest are between the percentage of patients with drug-related adverse events at each dose and placebo during single and multiple dosing regimens.
- Trial name
- NCT03971539
- Testing
- BI 894416
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Boehringer Ingelheim
Respiratory Syncytial Virus
A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age
The purpose of this study is to assess the incidence and associated healthcare utilization of RSV-associated, suspected LRTI in a general population of infants from birth up to 2 years of age, and also to assess the accuracy of a…
- Trial name
- NCT01995175
- Testing
- Nasal swab sampling, Blood sampling, Diary cards
- Where
- 23 sites in United States, Argentina and 6 more
- Volunteers
- 2,409 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)
This is a randomized, multi-center, parallel-group, active-controlled, double-blind study evaluating the effects of mometasone furoate (MF) dry powder inhaler (DPI) on bone mineral density (BMD) in subjects with asthma.
- Trial name
- NCT00394355
- Testing
- mometasone furoate dry powder inhaler, fluticasone propionate hydrofluoroalkane (HFA), montelukast
- Volunteers
- 566 people
- Sponsor
- Organon and Co
Airway Inflammation, Asthma
An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients
This is a randomised, active-comparator, open-label, parallel-group, multicentre phase IV exploratory study to characterise changes in airway inflammation, symptoms, lung function, and reliever use in asthma patients using SABA…
- Trial name
- NCT03924635
- Testing
- SYMBICORT and salbutamol
- Where
- 6 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Asthma
Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.
Primary Objective To demonstrate the non-inferiority of Foster® NEXThaler® 100/6 µg versus (vs.) Foster® pressurised metered dose inhaler (pMDI) 100/6 µg in terms of pulmonary function (change from baseline to the entire…
- Trial name
- FORTUNE (NCT03453112)
- Testing
- Foster 100/6µg NEXThaler, Foster 100/6µg pMDI
- Where
- 51 sites in China
- Volunteers
- 494 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma
Primary Objective: To evaluate the effect of dupilumab, compared to placebo, on airway inflammation in participants with persistent asthma.
- Trial name
- EXPEDITION (NCT02573233)
- Testing
- Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 42 people
- Sponsor
- Sanofi
Asthma
Pilot of Lifestyle and Asthma Intervention
This is to pilot test a weight loss intervention in obese patients with poorly controlled asthma. Obesity is a risk factor for the development of asthma (approximately 250,000 cases per year of asthma in the U.S.
- Trial name
- PLAN (NCT03291808)
- Testing
- Weight loss intervention
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Johns Hopkins University
Asthma
Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma
This is a randomized, double-blind, single-dose, placebo-controlled, 5-period, 5-treatment, crossover, multi-center study to assess the bronchodilatory effect and safety of 2 dose levels of Albuterol Sulfate Pressurized…
- Trial name
- NCT03364608
- Testing
- AS MDI 90 μg, AS MDI 180 µg, Proventil 90 μg
- Where
- 10 sites in United States
- Volunteers
- 86 people
- Sponsor
- AstraZeneca
Asthma
A Pilot Study to Improve Preventive Asthma Care for Urban Adolescents
The goal of this pilot study is to implement directly observed therapy with preventive asthma medications through a partnership with the school nurse (with input and direction from the primary care provider) to assure that the…
- Trial name
- NCT01106326
- Testing
- Intervention
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester
Asthma
Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics
This protocol describes a single site mechanistic study to investigate microRNAs (miRNAs) that are differentially expressed in the airway epithelium of patients with asthma at baseline and in response to allergen challenge.
- Trial name
- ACE (NCT02230189)
- Testing
- Segmental airway allergen challenge, Bronchoscopy, Methacholine challenge test
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Prescott Woodruff
Allergy, Asthma
Sublingual Cockroach Safety in Adults With Cockroach Allergy & Perennial Allergic Rhinitis With or Without Asthma
Immunotherapy may help reduce symptoms of allergy and asthma. Problems concerning compliance and adverse events with subcutaneous allergen immunotherapy have generated interest in delivering immunotherapy sublingually (under the…
- Trial name
- SCSS (NCT00434421)
- Testing
- Glycerinated German cockroach allergenic extract
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Evaluate the superiority of CHF 5993 200/6/12.5 µg pressurised metered dose inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) versus CHF 1535 200/6 µg…
- Trial name
- TRIGGER (NCT02676089)
- Testing
- CHF 5993 200/6/12.5 µg, CHF 1535 200/6 µg, CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
- Where
- 244 sites in Argentina, Belarus and 15 more
- Volunteers
- 1,437 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Disease
Study of Medical Student Use of Templates to Document Outpatient Asthma Care in Electronic Medical Record
The purpose of the study is to measure the effectiveness of a social marketing-based medical education intervention on student use of evidence-based templates for documenting outpatient asthma care within an electronic medical…
- Trial name
- NCT01043133
- Testing
- social marketing-based medical education intervention
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Uniformed Services University of the Health Sciences
Asthma
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma…
- Trial name
- NCT03186209
- Testing
- Benralizumab
- Where
- 79 sites in China, Philippines and 2 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Asthma
Sub-Sensitivity to Long-Acting Bronchodilators (LABA)
The purpose of this study is to look at whether Advair® and SYMBICORT® have different effects on airway constriction by means of methacholine challenge testing.
- Trial name
- NCT01117116
- Testing
- fluticasone propionate and salmeterol, budesonide and formoterol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Jewish Health
Asthma
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe…
- Trial name
- NATAIR (NCT01007149)
- Testing
- omalizumab
- Where
- 10 sites in France
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma
The primary purpose of the study is to assess the safety and tolerability of 52-week teatment with fluticasone furoate/GW642444 inhalation powder once-daily and FF inhalation powder once-daily in Japanese adult subjects with…
- Trial name
- NCT01244984
- Testing
- Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder
- Where
- 30 sites in Japan
- Volunteers
- 243 people
- Sponsor
- GlaxoSmithKline
Asthma
Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)
The purpose of this study is to assess the safety, tolerability \& effectiveness of 2 strengths of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in the treatment of persistent asthma in adults \&…
- Trial name
- NCT01566149
- Testing
- Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI, Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI
- Volunteers
- 49 people
- Sponsor
- Organon and Co
Asthma
Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects
The primary objective of this study is to evaluate the dose response, efficacy, and safety of 4 different doses of salmeterol Spiromax (6.25, 12.5, 25, and 50 mcg) each combined with a fixed dose of fluticasone propionate (100…
- Trial name
- NCT01772368
- Testing
- Fp MDPI, FS MDPI, Advair Diskus
- Where
- 10 sites in United States
- Volunteers
- 72 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma, Perennial Allergic Rhinitis
Biomarkers of Cockroach Sublingual Immunotherapy 2
This trial is a follow-up study of the ICAC-12 Phase I/II trial (NCT00829985), and is designed to study biomarkers of the immune response to allergen immunotherapy and the safety of this therapy in a pediatric population.
- Trial name
- BioCSI-2 (NCT01380327)
- Testing
- Cockroach Sublingual Immunotherapy (SLIT) - Low Dose, Cockroach Sublingual Immunotherapy (SLIT) - High Dose
- Where
- 5 sites in United States
- Volunteers
- 99 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)